Statistical linkage analysis of substitutions in patient-derived sequences of genotype 1a Hepatitis C virus nonstructural protein 3 exposes targets for immunogen design

Journal of Virology

Volumn 88, Issue 13, 2014, Pages 7628-7644

  Quadeer, Ahmed A ^a   Louie, Raymond H Y ^a   Shekhar, Karthik ^b,c   Chakraborty, Arup K ^a,b,c   Hsing, I Ming ^a   McKay, Matthew R ^a  

^a HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

^b Massachusetts Institute of Technology Cambridge   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HELICASE; NONSTRUCTURAL PROTEIN 3; PROTEINASE; NS3 PROTEIN, HEPATITIS C VIRUS; VIRUS PROTEIN;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIGEN PRESENTATION; ARTICLE; CRYSTAL STRUCTURE; ENZYME ACTIVITY; GENOTYPE; HAPLOTYPE; HEPATITIS C VIRUS SUBTYPE 1A; IMMUNE RESPONSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; SEQUENCE ANALYSIS; VIRAL CLEARANCE; VIRUS REPLICATION; CELLULAR IMMUNITY; GENETICS; HEPACIVIRUS; HEPATITIS C; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; METABOLISM; MUTATION; PROTEIN CONFORMATION; STATISTICAL ANALYSIS; VIROLOGY;

AMINO ACID SUBSTITUTION; DATA INTERPRETATION, STATISTICAL; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; IMMUNITY, CELLULAR; IMMUNODOMINANT EPITOPES; MUTATION; PROTEIN CONFORMATION; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84901999754     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03812-13     Document Type: Article

References (74)

1. World Health Organization. 2013. Factsheet, hepatitis C. World Health Organization, Geneva, Switzerland.
2. Lauer G, Walker B. 2001. Hepatitis C virus infection. N. Engl. J. Med. 345:41-52. http://dx.doi.org/10.1056/NEJM200107053450107.
3. Afdhal NH. 2004. The natural history of hepatitis C. Semin. Liver Dis. 24:3-8. http://dx.doi.org/10.1055/s-2004-832922.
4. National Institutes of Health. 2002. National Institutes of Health Consensus Development Conference statement: management of hepatitis C: 2002-June 10-12, 2002. Hepatology 36(Suppl 1):S3-S20. http://dx.doi .org/10.1053/jhep.2002.37117.
5. Grieve R, Roberts J, Wright M, Sweeting M, DeAngelis D, Rosenberg W, Bassendine M, Main J, Thomas H. 2006. Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C. Gut 55:1332-1338. http://dx.doi.org/10.1136/gut .2005.064774.
6. Dev A, Patel K, McHutchison J. 2004. New therapies for chronic hepatitis C virus infection. Curr. Gastroenterol. Rep. 6:77-86. http://dx.doi .org/10.1007/s11894-004-0030-5.
7. Booth JC, O'Grady J, Neuberger J; The Royal College of Physicians of London and the British Society of Gastroenterology. 2001. Clinical guidelines on the management of hepatitis C. Gut 49:I1-I21. http://dx.doi .org/10.1136/gut.49.suppl_1.I1.
8. Delang L, Neyts J, Vliegen I, Abrignani S, Neddermann P, De Francesco R. 2013. Hepatitis C virus-specific directly acting antiviral drugs, p 289-320. In Bartenschlager R (ed), Hepatitis C virus: from molecular virology to antiviral therapy. Springer, Berlin, Germany.
9. Halliday J, Klenerman P, Barnes E. 2011. Vaccination for hepatitis C virus: closing in on an evasive target. Expert Rev. Vaccines 10:659-672. http://dx.doi.org/10.1586/erv.11.55.
10. Moradpour D, Penin F, Rice CM. 2007. Replication of hepatitis C virus. Nat. Rev. Microbiol. 5:453-463. http://dx.doi.org/10.1038/nrmicro1645.
11. Perotti M, Mancini N, Diotti RA, Tarr AW, Ball JK, Owsianka A, Adair R, Patel AH, Clementi M, Burioni R. 2008. Identification of a broadly cross-reacting and neutralizing human monoclonal antibody directed against the hepatitis C virus E2 protein. J. Virol. 82:1047-1052. http://dx .doi.org/10.1128/JVI.01986-07.
12. Meunier J-C, Russell RS, Goossens V, Priem S, Walter H, Depla E, Union A, Faulk KN, Bukh J, Emerson SU, Purcell RH. 2008. Isolation and characterization of broadly neutralizing human monoclonal antibodies to the E1 glycoprotein of hepatitis C virus. J. Virol. 82:966-973. http: //dx.doi.org/10.1128/JVI.01872-07.
13. Klenerman P, Thimme R. 2012. T cell responses in hepatitis C: the good, the bad and the unconventional. Gut 61:1226-1234. http://dx.doi.org/10 .1136/gutjnl-2011-300620.
14. Timm J, Lauer GM, Kavanagh DG, Sheridan I, Kim AY, Lucas M, Pillay T, Ouchi K, Reyor LL, Schulze zur Wiesch J, Gandhi RT, Chung RT, Bhardwaj N, Klenerman P, Walker BD, Allen TM. 2004. CD8 epitope escape and reversion in acuteHCVinfection. J. Exp. Med. 200:1593-1604. http://dx.doi.org/10.1084/jem.20041006.
15. Söderholm J, Ahlén G, Kaul A, Frelin L, Alheim M, Barnfield C, Liljeström P, Weiland O, Milich DR, Bartenschlager R, Sällberg M.2006. Relation between viral fitness and immune escape within the hepatitis C virus protease. Gut 55:266-274. http://dx.doi.org/10.1136/gut .2005.072231.
16. Petrovic D, Dempsey E, Doherty DG, Kelleher D, Long A. 2012. Hepatitis C virus-T-cell responses and viral escape mutations. Eur. J. Immunol. 42:17-26. http://dx.doi.org/10.1002/eji.201141593.
17. Oniangue-Ndza C, Kuntzen T, Kemper M, Berical A, Wang YE, Neumann-Haefelin C, Foote PK, Hills-Evans K, Reyor LL, Kane K, Gladden AD, Bloom AK, Power KA, Thimme R, Lauer GM, Henn MR, Kim AY, Allen TM. 2011. Compensatory mutations restore the replication defects caused by cytotoxic T lymphocyte escape mutations in hepatitis C virus polymerase. J. Virol. 85:11883-11890. http://dx.doi.org/10.1128/JVI .00779-11.
18. Dahirel V, Shekhar K, Pereyra F, Miura T, Artyomov M, Talsania S, Allen TM, Altfeld M, Carrington M, Irvine DJ, Walker BD, Chakraborty AK. 2011. Coordinate linkage of HIV evolution reveals regions of immunological vulnerability. Proc. Natl. Acad. Sci. U. S. A. 108: 11530-11535. http://dx.doi.org/10.1073/pnas.1105315108.
19. Chang KM, Thimme R, Melpolder JJ, Oldach D, Pemberton J, Moorhead-Loudis J, McHutchison JG, Alter HJ, Chisari FV. 2001. Differential CD4+ and CD8+ T-cell responsiveness in hepatitis C virus infection. Hepatology 33:267-276. http://dx.doi.org/10.1053/jhep.2001.21162.
20. Schulze zur Wiesch J, Lauer GM, Day CL, Kim AY, Ouchi K, Duncan JE, Wurcel AG, Timm J, Jones AM, Mothe B, Allen TM, McGovern B, Lewis-Ximenez L, Sidney J, Sette A, Chung RT, Walker BD. 2005. Broad repertoire of the CD4+ Th cell response in spontaneously controlled hepatitis C virus infection includes dominant and highly promiscuous epitopes. J. Immunol. 175:3603-3613.
21. Fournillier A, Dupeyrot P, Martin P, Parroche P, Pajot A, Chatel L, Fatmi A, Gerossier E, Bain C, Lone YC, Trépo C, Inchauspé G. 2006. Primary and memory T cell responses induced by hepatitis C virus multiepitope long peptides. Vaccine 24:3153-3164. http://dx.doi.org/10.1016 /j.vaccine.2006.01.039.
22. Schulze Zur Wiesch J, Ciuffreda D, Lewis-Ximenez L, Kasprowicz V, Nolan BE, Streeck H, Aneja J, Reyor LL, Allen TM, Lohse AW, McGovern B, Chung RT, Kwok WW, Kim AY, Lauer GM. 2012. Broadly directed virus-specific CD4+ Tcell responses are primed during acute hepatitisCinfection, but rapidly disappear fromhumanblood with viral persistence. J. Exp. Med. 209:61-75. http: //dx.doi.org/10.1084/jem.20100388.
23. Wedemeyer H, Schuller E, Schlaphoff V, Stauber RE, Wiegand J, Schiefke I, Firbas C, Jilma B, Thursz M, Zeuzem S, Hofmann WP, Hinrichsen H, Tauber E, Manns MP, Klade CS. 2009. Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C. Vaccine 27:5142-5151. http://dx.doi.org/10.1016/j.vaccine .2009.06.027.
24. Diepolder HM, Gerlach JT, Zachoval R, Hoffmann RM, Jung MC, Wierenga EA, Scholz S, Santantonio T, Houghton M, Southwood S, Sette A, Pape GR. 1997. Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. J. Virol. 71: 6011-6019.
25. Bronowicki JP, Vetter D, Uhl G, Hudziak H, Uhrlacher A, Vetter JM, Doffoel M. 1997. Lymphocyte reactivity to hepatitis C virus (HCV) antigens shows evidence for exposure toHCVin HCV-seronegative spouses of HCV-infected patients. J. Infect. Dis. 176:518-522. http://dx.doi.org/10 .1086/517279.
26. Pang PS, Jankowsky E, Planet PJ, Pyle AM. 2002. The hepatitis C viral NS3 protein is a processive DNA helicase with cofactor enhanced RNA unwinding. EMBO J. 21:1168-1176. http://dx.doi.org/10.1093/emboj/21 .5.1168.
27. Rosen HR, Miner C, Sasaki AW, Lewinsohn DM, Conrad AJ, Bakke A, Bouwer HGA, Hinrichs DJ. 2002. Frequencies of HCV-specific effector CD4+ T cells by flow cytometry: correlation with clinical disease stages. Hepatology 35:190-198.
28. Raney KD, Sharma SD, Moustafa IM, Cameron CE. 2010. Hepatitis C virus non-structural protein 3 (HCV NS3): a multifunctional antiviral target. J. Biol. Chem. 285:22725-22731. http://dx.doi.org/10.1074/jbc .R110.125294.
29. Ferguson A, Mann J, Omarjee S, Ndung'u T, Walker BD, Chakraborty AK. 2013. Translating HIV sequences into quantitative fitness landscapes predicts viral vulnerabilities for rational immunogen design. Immunity 38:606-617. http://dx.doi.org/10.1016/j.immuni.2012.11.022.
30. Laloux L, Cizeau P, Potters M, Bouchaud J-P. 2000. Random matrix theory and financial correlations. Int. J. Theor. Appl. Financ. 03:391-397. http://dx.doi.org/10.1142/S0219024900000255.
31. Plerou V, Gopikrishnan P, Rosenow B, Amaral L, Guhr T, Stanley H.2002. Random matrix approach to cross correlations in financial data. Phys. Rev. E Stat. Nonlin. Soft Matter Phys. 65(Pt 2):066126. http://dx.doi .org/10.1103/PhysRevE.65.066126.
32. Halabi N, Rivoire O, Leibler S, Ranganathan R. 2009. Protein sectors: evolutionary units of three-dimensional structure. Cell 138:774-786. http://dx.doi.org/10.1016/j.cell.2009.07.038.
33. Schmidt J, Blum HE, Thimme R. 2013. T-cell responses in hepatitis B and C virus infection: similarities and differences. Emerg. Microbes Infect. 2:e15. http://dx.doi.org/10.1038/emi.2013.14.
34. Aurora R, Donlin M. 2009. Genome-wide hepatitis C virus amino acid covariance networks can predict response to antiviral therapy in humans. J. Clin. Invest. 119:225-236. http://dx.doi.org/10.1172/JCI37085.
35. Lara J, Xia G, Purdy M, Khudyakov Y. 2011. Coevolution of the hepatitis Cvirus polyprotein sites in patients on combined pegylated interferon and ribavirin therapy. J. Virol. 85:3649-3663. http://dx.doi.org/10.1128/JVI .02197-10.
36. Campo DS, Dimitrova Z, Mitchell RJ, Lara J, Khudyakov Y. 2008. Coordinated evolution of the hepatitis C virus. Proc. Natl. Acad. Sci. U. S. A. 105:9685-9690. http://dx.doi.org/10.1073/pnas.0801774105.
37. Schvoerer E, Moenne-Loccoz R, Murray JM, Velay A, Turek M, Fofana I, Fafi-Kremer S, Erba A-C, Habersetzer F, Doffoël M, Gut J-P, Donlin MJ, Tavis JE, Zeisel MB, Stoll-Keller F, Baumert TF. 2013. Hepatitis C virus envelope glycoprotein signatures are associated with treatment failure and modulation of viral entry and neutralization. J. Infect. Dis. 207: 1306-1315. http://dx.doi.org/10.1093/infdis/jit032.
38. Lara J, Tavis JE, Donlin MJ, Lee WM, Yuan H-J, Pearlman BL, Vaughan G, Forbi JC, Xia G-L, Khudyakov YE. 2012. Coordinated evolution among hepatitis C virus genomic sites is coupled to host factors and resistance to interferon. In Silico Biol. 11:213-224. http://dx.doi.org/10.3233 /ISB-2012-0456.
39. Murray JM, Moenne-Loccoz R, Velay A, Habersetzer F, Doffoël M, Gut J-P, Fofana I, Zeisel MB, Stoll-Keller F, Baumert TF, Schvoerer E. 2013. Genotype 1 hepatitis C virus envelope features that determine antiviral response assessed through optimal covariance networks. PLoS One 8:e67254. http://dx.doi.org/10.1371/journal.pone.0067254.
40. Kuiken C, Yusim K, Boykin L, Richardson R. 2005. The Los Alamos hepatitis C sequence database. Bioinformatics 21:379-384. http://dx.doi .org/10.1093/bioinformatics/bth485.
41. Tulino A, Verdú S. 2004. Random matrix theory and wireless communications. Now Publishers Inc., Hanover, MA. http://dx.doi.org/10.1561 /0100000001.
42. Couillet R, Debbah M. 2011. Random matrix methods for wireless communications. Cambridge University Press, Cambridge, United Kingdom. http://dx.doi.org/10.1017/CBO9780511994746.
43. Bouchaud J-P, Potters M. 2011. Financial applications of random matrix theory: a short review, p 824-850. In Akemann G, Baik J, and Di Francesco P (ed), The Oxford handbook of random matrix theory. Oxford University Press, Oxford, United Kingdom.
44. Nadakuditi RR, Edelman A. 2008. Sample eigenvalue based detection of high-dimensional signals in white noise using relatively few samples. IEEE Trans. Signal Process. 56:2625-2638. http://dx.doi.org/10.1109/TSP.2008 .917356.
45. Ranganathan R, Rivoire O. 2012. Note 109: a summary of SCA calculations. http://systems.swmed.edu/rr_lab/sca.html.
46. Storey JD, Tibshirani R. 2003. Statistical significance for genomewide studies. Proc. Natl. Acad. Sci. U. S. A. 100:9440-9445. http://dx.doi.org /10.1073/pnas.1530509100.
47. Saalau-Bethell S, Woodhead A. 2012. Discovery of an allosteric mechanism for the regulation of HCV NS3 protein function. Nat. Chem. Biol. 8:920-925. http://dx.doi.org/10.1038/nchembio.1081.
48. Mackintosh SG, Lu JZ, Jordan JB, Harrison MK, Sikora B, Sharma SD, Cameron CE, Raney KD, Sakon J. 2006. Structural and biological identification of residues on the surface of NS3 helicase required for optimal replication of the hepatitis C virus. J. Biol. Chem. 281:3528-3535. http: //dx.doi.org/10.1074/jbc.M512100200.
49. Zaki M, Jin S, Bystroff C. 2003. Mining residue contacts in proteins using local structure predictions. IEEE Trans. Syst. Man. Cybern. B Cybern. 33:789-801. http://dx.doi.org/10.1109/TSMCB.2003.816916.
50. Ogmen U, Keskin O, Aytuna AS, Nussinov R, Gursoy A. 2005. PRISM: protein interactions by structural matching. Nucleic Acids Res. 33(Web Server issue):W331-W336. http://dx.doi.org/10.1093/nar/gki585.
51. Thio C, Gao X, Goedert J. 2002. HLA-Cw* 04 and hepatitis C virus persistence. J. Virol. 76:4792-4797. http://dx.doi.org/10.1128/JVI.76.10 .4792-4797.2002.
52. Neumann-Haefelin C, McKiernan S, Ward S, Viazov S, Spangenberg HC, Killinger T, Baumert TF, Nazarova N, Sheridan I, Pybus O, von Weizsäcker F, Roggendorf M, Kelleher D, Klenerman P, Blum HE, Thimme R. 2006. Dominant influence of an HLA-B27 restricted CD8+ T cell response in mediating HCV clearance and evolution. Hepatology 43: 563-572. http://dx.doi.org/10.1002/hep.21049.
53. Neumann-Haefelin C, Oniangue-Ndza C, Kuntzen T, Schmidt J, Nitschke K, Sidney J, Caillet-Saguy C, Binder M, Kersting N, Kemper MW, Power KA, Ingber S, Reyor LL, Hills-Evans K, Kim AY, Lauer GM, Lohmann V, Sette A, Henn MR, Bressanelli S, Thimme R, Allen TM.2011. Human leukocyte antigen B27 selects for rare escape mutations that significantly impair hepatitis C virus replication and require compensatory mutations. Hepatology 54:1157-1166. http://dx.doi.org/10.1002/hep .24541.
54. Kim AY, Kuntzen T, Timm J, Nolan BE, Baca MA, Reyor LL, Berical AC, Feller AJ, Johnson KL, Wiesch Zur S, Robbins GK, Chung RT, Walker BD, Carrington M, Allen TM, Lauer GM. 2011. Spontaneous control of HCV is associated with expression of HLA-B*57 and preservation of targeted epitopes. Gastroenterology 140:686-696. http://dx.doi .org/10.1053/j.gastro.2010.09.042.
55. Hraber P, Kuiken C, Yusim K. 2007. Evidence for human leukocyte antigen heterozygote advantage against hepatitis C virus infection. Hepatology 46:1713-1721. http://dx.doi.org/10.1002/hep.21889.
56. Sajadi M, Shakeri N, Talwani R, Redfield R. 2010. Hepatitis C infection in HIV-1 natural viral suppressors. AIDS 24:1689-1695. http://dx.doi.org /10.1097/QAD.0b013e32833a2a32.
57. Ruiz-Mateos E, Machmach K, Romero-Sanchez MC, Ferrando-Martinez S, Viciana P, Del Val M, Muñoz-Fernandez MA, Genebat M, Leal M. 2011. Hepatitis C virus replication in Caucasian HIV controllers. J. Viral Hepat. 18:e350-e357. http://dx.doi.org/10.1111/j.1365-2893 .2010.01431.x.
58. Vita R, Zarebski L, Greenbaum JA, Emami H, Hoof I, Salimi N, Damle R, Sette A, Peters B. 2010. The immune epitope database 2.0. Nucleic Acids Res. 38(Database issue):D854-D862. http://dx.doi.org/10.1093/nar /gkp1004.
59. Maiers M, Gragert L, Klitz W. 2007. High-resolution HLA alleles and haplotypes in the United States population. Hum. Immunol. 68:779-788. http://dx.doi.org/10.1016/j.humimm.2007.04.005.
60. Neumann-Haefelin C, Frick DN, Wang JJ, Pybus OG, Salloum S, Narula GS, Eckart A, Biezynski A, Eiermann T, Klenerman P, Viazov S, Roggendorf M, Thimme R, Reiser M, Timm J. 2008. Analysis of the evolutionary forces in an immunodominant CD8 epitope in hepatitis C virus at a population level. J. Virol. 82:3438-3451. http://dx.doi.org/10 .1128/JVI.01700-07.
61. Reeves KL, McKinnon EJ, James IR. 2012. Correction for founder effects in host-viral association studies via principal components. Stat. Appl. Genet. Mol. Biol. 11:pii: /j/sagmb.2012.11.issue-4/1544-6115.1827/1544-6115.1827.xml. http://dx.doi.org/10.1515/1544-6115.1827.
62. Timm J, Li B, Daniels MG, Bhattacharya T, Reyor LL, Allgaier R, Kuntzen T, Fischer W, Nolan BE, Duncan J, Schulze zur Wiesch J, Kim AY, Frahm N, Brander C, Chung RT, Lauer GM, Korber BT, Allen TM.2007. Human leukocyte antigen-associated sequence polymorphisms in hepatitis C virus reveal reproducible immune responses and constraints on viral evolution. Hepatology 46:339-349. http://dx.doi.org/10.1002 /hep.21702.
63. Gaudieri S, Rauch A, Park LP, Freitas E, Herrmann S, Jeffrey G, Cheng W, Pfafferott K, Naidoo K, Chapman R, Battegay M, Weber R, Telenti A, Furrer H, James I, Lucas M, Mallal SA. 2006. Evidence of viral adaptation to HLA class I-restricted immune pressure in chronic hepatitis C virus infection. J. Virol. 80:11094-11104. http://dx.doi.org/10.1128/JVI .00912-06.
64. Ray SC, Fanning L, Wang X-H, Netski DM, Kenny-Walsh E, Thomas DL. 2005. Divergent and convergent evolution after a common-source outbreak of hepatitis C virus. J. Exp. Med. 201:1753-1759. http://dx.doi .org/10.1084/jem.20050122.
65. Rauch A, James I, Pfafferott K, Nolan D, Klenerman P, Cheng W, Mollison L, McCaughan G, Shackel N, Jeffrey GP, Baker R, Freitas E, Humphreys I, Furrer H, Günthard HF, Hirschel B, Mallal S, John M, Lucas M, Barnes E, Gaudieri S. 2009. Divergent adaptation of hepatitis C virus genotypes 1 and 3 to human leukocyte antigen-restricted immune pressure. Hepatology 50:1017-1029. http: //dx.doi.org/10.1002/hep.23101.
66. Shekhar K, Ruberman CF, Ferguson AL, Barton JP, Kardar M, Chakraborty AK. 2013. Spin models inferred from patient-derived viral sequence data faithfully describe HIV fitness landscapes. Phys. Rev. E Stat. Nonlin. Soft Matter Phys. 88:062705. http://dx.doi.org/10.1103/PhysRevE .88.062705.
67. Rai R, Deval J. 2011. New opportunities in anti-hepatitis C virus drug discovery: targeting NS4B. Antiviral Res. 90:93-101. http://dx.doi.org/10 .1016/j.antiviral.2011.01.009.
68. Jost L. 2006. Entropy and diversity. Oikos 113:363-375. http://dx.doi.org /10.1111/j.2006.0030-1299.14714.x.
69. Houghton M. 2009. The long and winding road leading to the identification of the hepatitis C virus. J. Hepatol. 51:939-948. http://dx.doi.org/10 .1016/j.jhep.2009.08.004.
70. Marčenko V, Pastur L. 1967. Distribution of eigenvalues for some sets of random matrices. Math. USSR-Sbornik 1:457-483. http://dx.doi.org/10 .1070/SM1967v001n04ABEH001994.
71. Geman S. 1980. A limit theorem for the norm of random matrices. Ann. Probab. 8:252-261. http://dx.doi.org/10.1214/aop/1176994775.
72. Silverstein J. 1985. The smallest eigenvalue of a large dimensional Wishart matrix. Ann. Probab. 13:1364-1368. http://dx.doi.org/10.1214/aop /1176992819.
73. Donoho D, Gavish M. 2013. The optimal hard threshold for singular values is 4/sqrt(3). arXiv Prepr. arXiv: 1305.5870. http://arxiv.org/abs/13 05.5870.
74. Amari S, Cichocki A, Yang H. 1996. A new learning algorithm for blind signal separation. Adv. Neural Infect. Process. Syst. 8:757-763.